Zishen Yutai Pill for Patients With Recurrent Implantation Failure

Inclusion Criteria: 1. Meet the diagnostic criteria for recurrent implantation failure; 2. Aged between 20-40 years old (inclusive) when oocytes were retrieved, and \<43 at enrollment; 3. Have at least 1 good-quality embryo for transfer; 4. Intend to undergo frozen-thawed embryo transfer; 5. Voluntary participation and signed informed consent. Exclusion Criteria: 1. Concomitant unresolved intrauterine lesions (e.g., intrauterine adhesions grade III-IV, endometrial polyps ≥1 cm, acute endometritis), endometriosis (ASRM stage ≥III), or adenomyosis (uterine volume ≥8 weeks of gestation) that affect embryo implantation; 2. Intend to undergo FET after preimplantation genetic testing (PGT), including aneuploidy screening (PGT-A), monogenic disease testing (PGT-M), chromosomal structural rearrangement testing (PGT-SR); 3. Thin endometrium (\<7 mm) before enrollment; 4. Concomitant severe genital malformations or genital neoplasms; 5. Contraindications to estrogen and progestogen (e.g., history of breast cancer); 6. Presence of medical contraindications to assisted reproductive technology, including that either partner has a severe psychiatric disorder, acute genitourinary tract infection, sexually transmitted disease, serious deleterious habit (e.g., drug abuse), or teratogenic exposure to radiation, toxic agent or medication that still under effect; or genetic diseases specified in the Law of the People's Republic of China on Maternal and Infant Health Care for which childbearing and PGT are contraindicated; or severe somatic diseases incompatible with pregnancy; or chromosomal abnormalities; 7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>1.5 × the upper limit of normal (ULN), or serum creatinine (Scr) \> ULN; 8. Presence of poorly controlled severe systemic diseases, including cardiovascular, digestive, endocrine, and autoimmune diseases (e.g., antiphospholipid syndrome, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis); 9. Use of traditional Chinese medicines with similar functions and indications to ZYP within 1 month before screening that may affect treatment efficacy. Chinese patent medicines such as Tiaojing Cuyun Pills, Kuntai Capsules, Peikun Pills, Qilin Pills, Jinfeng Pills, Gushen Antai Pills, and Chinese herbal decoctions containing Cuscutae Semen, Dipsaci Radix, Taxilli Herba, and Asini Corii Colla with kidney-tonifying and spleen-strengthening effects; 10. Allergy to any component of the study drugs; 11. Participated in another interventional trials within 1 month prior to enrollment; 12. Deemed unsuitable for this study by the investigator.